Intravenous Safety and Pharmacokinetics of a Novel Dimerizer Drug, AP1903, in Healthy Volunteers
- 1 August 2001
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 41 (8) , 870-879
- https://doi.org/10.1177/00912700122010771
Abstract
AP1903 is a novel gene‐targeted drug that is being developed for use in drug‐regulated cell therapies. An intravenous, single‐blind, placebo‐ and saline‐controlled, ascending‐dose study was performed...Keywords
This publication has 18 references indexed in Scilit:
- A Fas-based suicide switch in human T cells for the treatment of graft-versus-host diseaseBlood, 2001
- Cell Surface Tagging and a Suicide Mechanism in a Single Chimeric Human ProteinHuman Gene Therapy, 1999
- Herpes Simplex Virus Thymidine Kinase Gene Transfer for Controlled Graft-versus-Host Disease and Graft-versus-Leukemia: Clinical Follow-up and Improved New VectorsHuman Gene Therapy, 1998
- Redesigning an FKBP–ligand interface to generate chemical dimerizers with novel specificityProceedings of the National Academy of Sciences, 1998
- European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matchingBone Marrow Transplantation, 1997
- HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-Versus-LeukemiaScience, 1997
- Functional analysis of Fas signaling in vivo using synthetic inducers of dimerizationCurrent Biology, 1996
- Graft-versus-Host DiseaseNew England Journal of Medicine, 1991
- Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft‐versus‐leukaemia effectBritish Journal of Haematology, 1988
- Treatment of Donor Bone Marrow with Monoclonal Anti-T-Cell Antibody and Complement for the Prevention of Graft-Versus-Host DiseaseAnnals of Internal Medicine, 1986